Pharmacokinetics and CNS pharmacodynamics of the 5-HT1(A) agonist buspirone in humans following acute L-tryptophan depletion challenge

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 19, Issue 5, 1997, Pages 351-362

  Jagannathan, Vanitha ^a   Venitz, Jürgen ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Acute L tryptophan depletion; Buspirone; CNS pharmacodynamics; Cognitive tests; Cortisol; Electroencephalography; Mood; Pharmacokinetics; Prolactin

Indexed keywords

BUSPIRONE; PLACEBO; SEROTONIN AGONIST; TRYPTOPHAN;

ADULT; ARTICLE; BLOOD BRAIN BARRIER; BLOOD SAMPLING; CENTRAL NERVOUS SYSTEM FUNCTION; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; ELECTROENCEPHALOGRAPHY; HORMONE RESPONSE; HUMAN; HUMAN EXPERIMENT; MALE; NEUROTRANSMITTER RELEASE; NORMAL HUMAN; PSYCHOMETRY; RANDOMIZED CONTROLLED TRIAL; RATING SCALE;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTI-ANXIETY AGENTS; AREA UNDER CURVE; BUSPIRONE; CENTRAL NERVOUS SYSTEM; COGNITION; CROSS-OVER STUDIES; DIET; DOUBLE-BLIND METHOD; ELECTROENCEPHALOGRAPHY; HUMANS; HYDROCORTISONE; MALE; PROLACTIN; SEROTONIN AGONISTS; SINGLE-BLIND METHOD; TRYPTOPHAN;

EID: 0030883423     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Eison, A.S., Temple, D.L. Buspirone: Review of its pharmacology and current perspectives on its mechanism of action. Am J Med 1986, 80 (Suppl. 3B): 1-9.
2. Young, S.N. The use of diet and dietary components in the study of factors controlling affect in humans: A review. J Psychiatr Neurosci 1993, 18: 235-44.
3. Young, S.N., Pihl, R.O., Ervin, F.R. The effect of altered tryptophan levels on mood and behavior in normal human males. Clin Neuropharmacol 1988, 11 (Suppl. 1): S207-15.
4. Moja, E.A., Stoff, D.M., Gessa, G.L., Castoldi, D., Assereto, R., Tofanetti, O. Decrease in plasma tryptophan after tryptophan-free amino acid mixtures in man. Life Sci 1988, 42: 1551-6.
5. Smith, S.E., Pihl, R.O., Young, S.N., Ervin, F.R. A test of possible cognitive and environmental influences on mood lowering effect of tryptophan depletion in normal males. Psychopharmacology 1987, 91: 451-7.
6. Miller, H.L., Delgado, P.L., Salomon, R.M., Licinio, J., Barr, L.C., Charney, D.S. Acute tryptophan depletion: A method of studying antidepressant action. J Clin Psychiatry 1992, 53 (Suppl. 10): 28-35.
7. Young, S.N., Smith, S.E., Pihl, R.O., Ervin, FR. Tryptophan depletion causes a rapid lowering of mood in normal males. Psychopharmacology 1985, 87: 173-7.
8. Wesnes, K., Simpson, P., Christmas, L. The assessment of human information-processing abilities in psychopharmacology. In: The Human Psychopharmacology Series. Hindmarch, I., Stonier, P.D. (Eds.). John Wiley: Chichester/ New York 1987, 79-92.
9. Norris, H. The action of sedatives on brain stem oculomotor systems in man. Neuropharmacology 1971, 10: 181-91.
10. Bond, A., Lader, M. The use of analogue scales in rating subjective feelings. Br J Mcd Psychol 1974, 47: 211-8.
11. Jagannathan, V., March, C., Venitz, J. Determination of unbound L-tryptophan in human plasma using high performance liquid chromatography with fluorescence detection. Biomed Chromatogr 1995, 9: 305-8.
12. lA agonist, buspirone in a human model of experimental depression. Dissertation, Medical College of Virginia, Virginia Commonwealth University, 1995.
13. Gibaldi, M., Perrier, D. Noncompartmental analysis based on statistical moment theory. In: Pharmacokinetics, Second Edition. Marcel Dekker 1982, 409-17.
14. Barbhaiya, R.H., Shukla, U.A., Pfeffer, M. et al. Disposition kinetics of buspirone in patients with renal or hepatic impairment after administration of single and multiple doses. Eur J Clin Pharmacol 1994, 46: 42-7.
15. Caccia, S., Vigano, G.L., Mingardi, G. et al. Clinical pharmacokinetics of oral buspirone in patients with impaired renal function. Clin Pharmacokinet 1988, 14: 171-7.
16. Dalhoff, K., Poulsen, H.E., Garred, P. et al. Buspirone pharmacokinetics in patients with cirrhosis. Br J Clin Pharmacol 1987, 24: 547-50.
17. Gammans, R.E., Mayol, R.F., LaBudde, J.A. Metabolism and disposition of buspirone. Am J Med 1986, 80 (Suppl. 3B): 41-51.
18. Gammans, R.E., Westrick, M.L., Shea, J.P., Mayol, R.F., LaBudde, J.A. Pharmacokinetics of buspirone in elderly subjects. J Clin Pharmacol 1989, 29: 72-8.
19. Anderson, I.M., Cowen, P.J., Grahame-Smith, D.G. The effects of gepirone on neuroendocrine function and temperature in humans. Psychopharmacology 1990, 100: 498-503.
20. Cohn, J.B., Wilcox, C.S., Meltzer, H.Y. Neuroendocrine effects of buspirone in patients with generalized anxiety disorder. Am J Med 1986, 80: 36-40.
21. Moeller, F.G., Steinberg, J.L., Fulton, M., Kramer, G., Petty, F. A preliminary neuroendocrine study with buspirone in major depression. Neuropsychopharmacology 1994, 10: 75-83.
22. Tollefson, G.D., Godes, M., Montague-Clouse, J., Laneaster, S.P., Garvey, M.J. Buspirone: Effects on prolactin and growth hormone as a function of drug level in generalized anxiety. J Clin Psychopharmacol 1989, 9: 132-6.
23. Seppala, T., Ranta, T., Shrotriya, R.C. Serum prolactin levels after buspirone in man. Med Biol 1987, 65: 61-3.
24. Anderson, I.M., Cowen, P.J. Effect of pindolol on endocrine and temperature responses to buspirone in healthy volunteers. Psychopharmacoloey 1992, 106: 428-32.
25. la receptor function in impulsive aggressive behavior in humans. Psychopharmacol Bull 1990, 26: 393-405.
26. Mattila, M., Seppala, T. Combined effects of buspirone and diazepam on objective and subjective tests of performance in healthy volunteers. Clin Pharmacol Ther 1986, 40: 620-6.
27. Smiley, A. Effects of minor tranquilizers and antidepressants on psychomotor performance. J Clin Psychiatry 1987, 48: 12 (Suppl.): 22-8.
28. Schaffler, K., Klausnitzer, W. Single dose study on buspirone versus diazepam in volunteers. Arzneim-Forsch/Drug Res 1988, 38(I): 282-7.
29. Boulenger, J.P., Squillance, K., Simon, P., Herrou, M., Leymarie, P., Zarifian, E. Buspirone and diazepam: Comparison of subjective, psychomotor and biological effects. Neuropsychobiology 1989, 22: 83-9.
30. De Roeck, J., Cluydts, R., Schotte, C., Roukhout. D., Cosyns, P. Explorative single-blind study on the sedative and hypnotic effects of buspirone in anxiety patients. Acta Psychiatr Scand 1989, 79: 129-35.
31. Murasaki, M., Miura, S., Ishigooka, J., Ishiii, Y., Takahashi, A., Fukuyama, Y. Phase I study of a new antianxiety drug, buspirone. Prog Neuropsychopharmacol Biol Psychiat 1989, 13: 137-44.
32. Blom, M.W., Bartel, P.R., Sommers, D.K., Van Der Meyden, C.H., Becker, P.J. The comparison of the effects of multi and single doses of buspirone, chlordiazepoxide and hydroxyzine on psychomotor function and EEG. Fundam Clin Pharmacol 1992, 6: 5-9.
33. Greenblatt, D.J., Harmatz, J.S., Gouthro, T.A., Locke, J., Shader, R.I. Distinguishing a benzodiazepine agonist (triazolam) from a nonagonist anxiolytic (buspirone) bv electroencephalography: Kinetic-dynamic studies. Clin Pharmacol Ther 1994, 56: 100-11.
34. Holland, R.L., Wesnes, K., Dietrich, B. Single dose human pharmacology of umespirone. Eur J Clin Pharmacol 1994, 46: 461-8.
35. Barbanoj, M.J., Antonijoan, R., Jane, F. Buspirone and electroencephalography. Clin Pharmacol Ther 1995, 55.